The present invention relates to the use of SGLT-2 inhibitors and/or an interleukin-1-receptor antagonist or a non-agonist antibody reactive to IL-1 or IL-1R in the treatment of prevention of symptomatic hypoglycaemia after bariatric surgery.

The present invention relates to a composition comprising a lithium salt of an N-substituted glycine compound and a carrier, wherein the lithium salt of the N-substituted glycine compound is of Formula (I): ##STR00001##
in which R.sup.1, R.sup.2, and R.sup.3 each are independently hydrogen, alkyl, alkenyl, alkynyl, aralkyl, carbocyclyl, aryl, or heteroaryl, or one of R.sup.1, R.sup.2, and R.sup.3 is absent. Also provided in the present invention is a method of mitigating at least one symptom of a neuropsychiatric disorder, comprising administering to a subject in need thereof the lithium salt of an N-substituted glycine compound of Formula (I).

The present invention relates to a composition comprising a lithium salt of an N-substituted glycine compound and a carrier, wherein the lithium salt of the N-substituted glycine compound is of Formula (I): ##STR00001##
in which R.sup.1, R.sup.2, and R.sup.3 each are independently hydrogen, alkyl, alkenyl, alkynyl, aralkyl, carbocyclyl, aryl, or heteroaryl, or one of R.sup.1, R.sup.2, and R.sup.3 is absent. Also provided in the present invention is a method of mitigating at least one symptom of a neuropsychiatric disorder, comprising administering to a subject in need thereof the lithium salt of an N-substituted glycine compound of Formula (I).

The present invention provides a pharmaceutical composition useful for preventing or treating a bone disease associated with an abnormality in the balance between osteoclasts and osteoblasts, particularly bone diseases accompanied by inflammation, such as periodontal diseases. The pharmaceutical composition for preventing or treating a bone disease according to the present invention contains a GPR40 agonist and a free fatty acid that is an endogenous ligand of GPR40.

The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.

The present invention comprises a composition with means to inhibit an autoimmune response and methods for using this composition to treat glaucoma and optic neuropathy.

The present invention comprises a composition with means to inhibit an autoimmune response and methods for using this composition to treat glaucoma and optic neuropathy.

The present invention comprises a composition with means to inhibit an autoimmune response and methods for using this composition to treat glaucoma and optic neuropathy.

The invention features compositions and methods for inhibiting the Pin1 protein, and the treatment of disorders characterized by elevated Pin1 levels.

The invention features compositions and methods for inhibiting the Pin1 protein, and the treatment of disorders characterized by elevated Pin1 levels.